Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), as well as develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company offers SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants; AFECTAIR device, a disposable aerosol-conducting airway connector for infants; and WARMING CRADLE, a dry-block heating device that is designed to warm drug vials at the same temperature that is designated in the SURFAXIN prescribing information. It is also developing AEROSURF, a drug/device combination product that delivers KL4 surfactant in aerosolized form using the lyophilized KL4 surfactant is in Phase II clinical trials for the treatment of RDS in premature infants. In addition, the company is developing a lyophilized (freeze-dried) dosage form of its KL4 surfactant. The company has a collaboration agreement with Battelle Memorial Institute for the development and commercialization of AEROSURF; and a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.